The Wall Street Journal reports a significant development for biotech firm Genentech. Medicare officials say the program will cover the clot dissolving drug tPA for patients who have suffered serous strokes. Officials note the drug costs about $2,000 per dose but say the drug's track record merits the investment.
- see this story from The Wall Street Journal (sub. req.)